We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
Follow the company to be always up to date with this company
Eligen® Technology Mechanism of Action
Emisphere Restructures Debt Agreements, Providing Greater Stability for Business Growth and Expansion
Emisphere Highlights Eligen Licensee Novo Nordisk’s Entry into Phase 3A Development of Oral Semaglutide
Emisphere Signs License Agreement with Novo Nordisk to Develop Oral Formulations of Four Molecules Targeting Metabolic Indications